Non-carrier added Lutetium-177 (n.c.a. Lu-177) is emerging as a radioisotope of choice for targeted radionuclide therapy.
This radioisotope is currently being supplied for a range of clinical trials in Australia. Watch our video below to find out more.
Review full product details.
View order cut-off and delivery schedule (PDF, 134.8 KB)online.
Other useful information: SAS form required by customer
If you have any further questions please get in touch with our customer service team.